shutterstock_761244463_casimiro_pt
Casimiro PT / Shutterstock.com
19 December 2019AmericasRory O'Neill

Supermarket chain settles pay-for-delay suit over birth control pill

Dutch supermarket owner Ahold Delhaize has agreed to settle a series of patent infringement suits filed against pharmaceutical companies including Warner Chilcott and Watson over contraceptive pill Loestrin 24 Fe.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
23 February 2016   The US Court of Appeals for the First Circuit has revived claims that pay-for-delay settlements involving pharmaceutical company Warner Chilcott may be in breach of competition law, despite the deals not including cash payments.
Americas
8 January 2020   Allergan’s Warner Chilcott and Watson subsidiaries have agreed to pay $300 million to end antitrust litigation centering on contraceptive pills Loestrin 24 Fe and Minastrin 24 Fe.

More on this story

Americas
23 February 2016   The US Court of Appeals for the First Circuit has revived claims that pay-for-delay settlements involving pharmaceutical company Warner Chilcott may be in breach of competition law, despite the deals not including cash payments.
Americas
8 January 2020   Allergan’s Warner Chilcott and Watson subsidiaries have agreed to pay $300 million to end antitrust litigation centering on contraceptive pills Loestrin 24 Fe and Minastrin 24 Fe.

More on this story

Americas
23 February 2016   The US Court of Appeals for the First Circuit has revived claims that pay-for-delay settlements involving pharmaceutical company Warner Chilcott may be in breach of competition law, despite the deals not including cash payments.
Americas
8 January 2020   Allergan’s Warner Chilcott and Watson subsidiaries have agreed to pay $300 million to end antitrust litigation centering on contraceptive pills Loestrin 24 Fe and Minastrin 24 Fe.